| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
PERSPECTIVE |
1 From the Center for Human Nutrition and the Departments of Clinical Nutrition and Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
ABSTRACT
"The metabolic syndrome" is the name for a clustering of risk factors for cardiovascular disease and type 2 diabetes that are of metabolic origin. These risk factors consist of atherogenic dyslipidemia, elevated blood pressure, elevated plasma glucose, a prothrombotic state, and a proinflammatory state. There are 2 major, interacting causes of the metabolic syndrome—obesity and endogenous metabolic susceptibility. The latter typically is manifested by insulin resistance. The metabolic syndrome is accompanied by a 2-fold increase in the risk of cardiovascular disease and a 5-fold increase in the risk of type 2 diabetes. A clinical diagnosis of the metabolic syndrome is useful because it affects therapeutic strategy in patients at higher risk. However, there are 2 views about the best therapeutic strategy for patients with the metabolic syndrome. One view holds that each of the metabolic risk factors should be singled out and treated separately. The other view holds that greater emphasis should be given to implementing therapies that will reduce all of the risk factors simultaneously. The latter approach emphasizes lifestyle therapies (weight reduction and increased exercise), which target all of the risk factors. This approach is also the foundation of other therapies for targeting multiple risk factors together by striking at the underlying causes, as in the development of drugs to promote weight reduction and to reduce insulin resistance. Treating the underlying causes does not rule out the management of individual risk factors, but it will add strength to the control of multiple risk factors.
Key Words: Metabolic syndrome • cardiovascular disease • risk factors • blood pressure • diabetes
This article has been cited by other articles:
|
|
 |
|
  L. Berglund, M. Lefevre, H. N Ginsberg, P. M Kris-Etherton, P. J Elmer, P. W Stewart, A. Ershow, T. A Pearson, B. H Dennis, P. S Roheim, et al. Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1611 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Oda Definition of Metabolic Syndrome Stroke, November 1, 2007; 38(11): e152 - e152. [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Blaum, N. A. West, and M. N. Haan Is the Metabolic Syndrome, With or Without Diabetes, Associated With Progressive Disability in Older Mexican Americans? J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2007; 62(7): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Q. Shaibi, M. L. Cruz, M. J. Weigensberg, C. M. Toledo-Corral, C. J. Lane, L. A. Kelly, J. N. Davis, C. Koebnick, E. E. Ventura, C. K. Roberts, et al. Adiponectin Independently Predicts Metabolic Syndrome in Overweight Latino Youth J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1809 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kahn Metabolic Syndrome: Is It a Syndrome? Does It Matter? Circulation, April 3, 2007; 115(13): 1806 - 1811. [Full Text] [PDF]
|
|
|
|
|
|
A. M Zivkovic and J B. German Individual variation in the metabolic syndrome: a new perspective on the debate Am. J. Clinical Nutrition, January 1, 2007; 85(1): 240 - 241. [Full Text] [PDF]
|
|
|
|
|
|
E. Oda Criteria for diagnosing the metabolic syndrome. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 1251 - 1252. [Full Text] [PDF]
|
|
|
|
|
|
G. Reaven Reply to E Oda Am. J. Clinical Nutrition, November 1, 2006; 84(5): 1252 - 1252. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
